The Measurement of Anti-Müllerian Hormone: A Critical Appraisal

Rustamov, Oybek; Smith, Alwyn; Roberts, Stephen A; Yates, Allen P.; Fitzgerald, Cheryl; Krishnan, Monica; Nardo, Luciano G.; Pemberton, Philip W.

doi:10.1210/jc.2013-3476

Cited by 79 publications

(64 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thereafter, two proprietary AMH assay kits, Active AMH and EIA AMH/MIS [Diagnostic Systems Laboratory (DSL) and Immunotech (IOT)] were brought to market. Each kit used different AMH antibodies, resulting in different assay ranges and different inter-and intraassay coefficients of variation [116,117]. Beckman Coulter merged DSL and IOT and developed a new AMH assay kit (AMH GenII).…”

Section: Standardization Of the Amh Assaymentioning

confidence: 99%

Anti‐Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Iwase

Nakamura

Osuka

et al. 2015

Reprod Medicine & Biology

View full text Add to dashboard Cite

Ovarian reserve reflects the quality and quantity of available oocytes. This reserve has become indispensable for the better understanding of reproductive potential. Measurement of the serum anti-Müllerian hormone (AMH) level allows quantitative evaluation of ovarian reserve. It has been applied to a wide range of clinical conditions, and it is well established that the measurement of serum AMH levels is more useful than qualitative evaluation based on the menstrual cycle. AMH levels are monitored during infertility treatments; in patients undergoing medically assisted reproductive technology; and in the diagnosis of ovarian failure, polycystic ovarian syndrome, and granulosa cell tumor. It is also useful in the evaluation of iatrogenic ovarian damage. Population-based studies have indicated a potential role for serum AMH in the planning of reproductive health management. While AMH is currently the best measure of ovarian reserve, its predictive value for future live births remains controversial. Furthermore, there is a serious practical issue in the interpretation of test results, as currently available assay kits use different assay ranges and coefficients of variation due to the absence of an international reference standard. The pros and cons of the serum AMH level as a definitive measure of ovarian reserve merits further review in order to guide future research.

show abstract

Section: Standardization Of the Amh Assaymentioning

confidence: 99%

Anti‐Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Iwase

Nakamura

Osuka

et al. 2015

Reprod Medicine & Biology

View full text Add to dashboard Cite

show abstract

“…The effect of thawing on the AMH results, especially after repeated freeze-thaw cycles, was also recently discussed in the review by Rustamov et al [12]. Few studies have been published on this matter, although the publications dealing with AMH levels in different clinical settings have increased enormously over the past 10-15 years since AMH methods became clinically available.…”

Section: Discussionmentioning

confidence: 99%

“…These findings questioned the robustness of the AMH assays in different settings. Furthermore, it has been suggested that AMH assays may exhibit pre-analytical variability with probable influence on sample handling in the laboratory and perhaps also on long-term stability [12]. Until now, few studies have been conducted on the impact of longterm freezer storage on AMH results [12].…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, it has been suggested that AMH assays may exhibit pre-analytical variability with probable influence on sample handling in the laboratory and perhaps also on long-term stability [12]. Until now, few studies have been conducted on the impact of longterm freezer storage on AMH results [12]. The influence on AMH results after intermittent thawing-which is often required in long-term studies-has also been discussed, as analytical methods improve and change over time [13,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reliability of AMH in Serum after Long-term Storage at -80°C and an Extended Thawing Episode

Mörse¹,

Öra²,

Turkiewicz

et al. 2016

Ann Clin Lab Res

View full text Add to dashboard Cite

“…AMH has the advantage of having relatively stable levels throughout the menstrual cycle [49,50] and is more accurate in providing information on the expected ovarian response to controlled stimulation [50]. However, AMH is limited in extreme responses as it is not reliably predictive in this situation, and also its value has been questioned [51]. Nevertheless, considering the important role of the AMH signaling pathway in regulating sensitivity in the ovary and follicular recruitment, it is appropriate to consider that variation in the genes encoding key proteins in the pathway may influence ovarian response.…”

Section: Cellular Physiology and Biochemistrymentioning

confidence: 99%

Associations of Polymorphisms in Anti-Müllerian Hormone (AMH Ile49Ser) and its Type II Receptor (AMHRII -482 A>G) on Reproductive Outcomes and Polycystic Ovary Syndrome: a Systematic Review and Meta-Analysis

Pabalan

Montagna

Singian

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Reported associations of reproductive outcomes (RO) and polycystic ovary syndrome (PCOS) with genotypes of the Ile49Ser and -482A>G polymorphisms in the Anti-Müllerian hormone (AMH) gene and its type II receptor (AMHRII), respectively, have conflicting results. Methods: PubMed, Google Scholar and Science Direct databases were searched for studies that investigated Ile49Ser and -482A>G in RO and PCOS. Using the metaanalytic approach, we estimated risk (odds ratio [OR] with 95% confidence intervals) using standard genetic models. Results: All calculated summary effects were non-significant. Overall associations of Ile49Ser and -482A>G with RO were absent (OR 0.95-0.99, P = 0.76-0.96) but implied increased risk in PCOS (OR 1.07-1.17, P = 0.49-0.55). Where heterogeneity of the pooled ORs were present, its sources were explored using the Galbraith plot. Detection and omission of the outlying studies in both polymorphisms not only erased heterogeneity of the recalculated pooled outcomes but also changed direction of association, where null effects turned to increased risk (Ile49Ser in RO) and increased risk became reduced risk (-482A>G in PCOS). Implications of the Ile49Ser and -482A>G, effects pointed to protection for Caucasians (OR 0.64-0.89, P = 0.36-0.73) in RO and increased risk in PCOS (OR 1.19-1.45, P = 0.28-0.65). Asian effects in RO and PCOS were variable (OR 0.97-1.24, P = 0.58-0.91). Conclusions: In summary, we found no evidence of significant associations of Ile49Ser and -482A>G with RO and PCOS, although contrasting Ile49Ser effects were implied among Caucasians between RO (up to 0.36% reduced risk) and PCOS (up to 1.5-fold increased risk).

show abstract

The Measurement of Anti-Müllerian Hormone: A Critical Appraisal

Abstract: AMH may exhibit assay-specific preanalytical instability. Robust protocols for the development and validation of commercial AMH assays are required.

Cited by 79 publications

References 46 publications

Anti‐Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Anti‐Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Reliability of AMH in Serum after Long-term Storage at -80°C and an Extended Thawing Episode

Associations of Polymorphisms in Anti-Müllerian Hormone (AMH Ile49Ser) and its Type II Receptor (AMHRII -482 A>G) on Reproductive Outcomes and Polycystic Ovary Syndrome: a Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About